Belle: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinbelle.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.”

2. 2

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Belle” on the pictured label, suggesting Belle is the compounder of those drugs when in fact it is not.”

3. 3

   “Accordingly, the representations on your website that Belle is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

joinbelle.com returned a live storefront on 2026-08-09, titled "Belle | Online GLP-1 Weight Loss & Longevity Care", with published monthly prices and the Draper, Utah location the letter gives.

Most letters in this collection are about a sentence someone wrote. This one is about a photograph. FDA quoted no claim from Belle's site — no "same active ingredient", no brand name, nothing — and still issued the letter, because the vial in the product image had the seller's name on it and the seller does not compound. That tells you something the wordier letters obscure: the impression that a telehealth brand makes its own medicine can be created without a single word of copy, and reading the fine print more carefully would not have caught it. For a price comparison it means the same thing it means everywhere else here — the name on the vial is not the name of the manufacturer, so it is not a quality signal you can price, and the company behind the actual product is not disclosed on the page where you choose.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Belle failed to respond.